Heplisav Vaccine Postmarketing Study Might Overcome FDA Safety Worries At Panel

 
• By Michael Cipriano

Dynavax has already received two complete response letters for its hepatitis B vaccine; more patients who received Heplisav died or experienced cardiovascular events compared with the competitor arm.

Large US American flag on sailboat off the coast of California
Dynavax likely won't have as smooth sailing at its advisory committee for Heplisav.

More from US FDA Performance Tracker

More from Regulatory Trackers